EvaluatePharma’s report “World Preview 2018, Outlook to 2024” pointed out that Abbott Biotech drug Adalimumab will still defend the world’s best-selling drug list winner in 2024. Novartis will surpass Pfizer and Roche in 2024 to become the world’s largest prescription drug company with US$53.2 billion in revenue.
In the increasingly favoured environment for the development of biological products and similar drugs, what is the market pattern of biological products in 2024?
The Evaluate Pharma report shows that the market for biological products is increasing, which will increase from 25% in 2017 to 31% in 2024. In particular, 2024 TOP100 prescription drug products, biological products will rise from 49% in 2017 to 52% in 2024. This growth trend has prompted more and more companies to develop biological products.
Trends in Global Biological Product Sales from 2010 to 2024
In 2024, Roche’s biological product sales will reach 42.1 billion U.S. dollars (83% of total revenue). There is no suspense to become the biggest winner in sales of biological products. It also highlights Roche’s acquisition of biotech pioneer Genentech and continuous investment in biotechnology products. And get the long-term value.
Sanofi’s sales of biological products will surpass Amgen, Johnson & Johnson, and Aibo Wei, and will leap to second place at a compound annual growth rate of 10% to US$26.2 billion. Its growth is mainly reflected in the brand value and the products of Recycling Products. Cooperation (Dupixent, Praluent, Kevzara).
Since the sale of PD-1 drug Keytruda is expected to increase substantially, analysts expect that MSD will achieve a compound annual growth rate of 11% to US$22.9 billion, ranking third in the list.
The sales ranking of BMS bioproducts with great popularity for PD-1 drugs will also increase significantly in 2024. Sales volume will increase at a compound annual growth rate of 9% from US$9 billion in 2017 to US$16.1 billion.
Although Epstein uses a number of pipeline assets to offset the loss of adalimumab patents and biosimilar drug products, there is only one important product on the company’s biological product pipeline, namely the IL-23 inhibitor risankizumab; Rova-T, a biological product asset, suffered a significant downgrade this year by analysts. Analysts expect that AbbV Bio’s overall sales will show a negative compound growth rate. In 2024, the revenue of this sector will be only US$17.7 billion, which is less than US$19.3 billion in 2017.
It is worth mentioning that the EvaluatePharma report predicted that the 2024 prescription drug sales champion Novartis failed to enter TOP10 in the sales of biological products; Pfizer, the second top Pfizer in the total list, was also rubbing its shoulders with only $14 billion 600 million in biological products to get into the tenth place.
2024 global sales of biological products TOP10 companies